Publisher Post

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed metus velit, aliquam in ornare ut, congue vel odio. Vestibulum ultrices velit in orci ullamcorper, tempus adipiscing urna placerat. Curabitur erat ipsum, gravida dignissim eleifend at, molestie sed magna. Ut velit arcu, hendrerit sed justo id, porta tristique eros. Morbi luctus nulla arcu, in imperdiet neque venenatis at. Nulla a tortor nec tortor viverra mattis quis vel ligula. Suspendisse fringilla aliquam massa vitae consequat. Ut auctor purus tortor, vel tincidunt leo porttitor sit amet. Phasellus pharetra odio non purus varius imperdiet. In porttitor luctus massa, id tincidunt felis tincidunt vel. Cras tincidunt, nunc eu euismod scelerisque, augue neque suscipit ligula, eu vehicula nunc lorem non erat. Duis ac nisi sed lectus molestie varius. Mauris vitae ligula nisi. Donec ullamcorper ultrices nibh vitae blandit. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Aliquam cursus sapien id diam laoreet lobortis. Morbi tincidunt dignissim nibh, at commodo massa blandit id. Mauris fringilla eleifend nulla, ac euismod sem placerat et. Morbi a nisi lorem. Donec hendrerit non mauris sed tincidunt. Nullam bibendum tempor leo quis elementum. In mollis dui vel mollis sagittis. Donec lorem nulla, placerat a vestibulum vel, rutrum ut augue. Sed et dapibus leo, vitae placerat odio. Donec malesuada vitae dolor sed fermentum. Nulla dignissim arcu augue, et sagittis metus suscipit vitae. Aliquam rutrum erat enim, at tempor diam semper vel. Suspendisse potenti. Nam et iaculis lectus, vitae vehicula dolor. Aenean sit amet tincidunt metus, vel eleifend erat. Nam est dui, adipiscing eget ultricies non, ultricies sit amet lacus. Morbi at rhoncus erat. Vestibulum ac arcu imperdiet...

Ambrx and Zhejiang Medicine Co. Ltd. Form Collaboration to Develop and Commercialize Ambrx’s Antibody Drug Conjugate for Breast Cancer

San Diego and Shanghai June 14, 2013 Ambrx and Zhejiang Medicine Co. Ltd. (ZMC) today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx’s most advanced internally developed site-specific antibody drug conjugate (ADC) targeting Her2-positive breast cancer. Under the agreement, Ambrx and ZMC will continue the development of ARX788, with ZMC bearing the ongoing development cost. ZMC will receive commercial rights in China while Ambrx retains commercial rights outside of China and receives royalties on sales of the product in China. ZMC will manufacture the product to world-class standards for clinical and commercial supplies on a global basis. WuXi PharmaTech will provide integrated services for ARX788, including the development and manufacturing of the toxin, antibody and ADC, pre-clinical development and clinical trials. “We are excited to initiate this unique collaboration with ZMC and WuXi, which allows us to team up with China’s leading pharmaceutical and CRO companies to efficiently develop ARX788, our most advanced ADC therapeutic candidate for both breast cancer and gastric cancer indications,” said Lawson Macartney, Ph.D., Chief Executive Officer of Ambrx. “This collaboration allows Ambrx to further extend our pipeline of ADCs and gain access to the China market through our partnership with ZMC. Our experience with site-specific ADC technology has shown that we have the potential to create best-in-class therapeutic candidates, and we look forward to advancing ARX788 into the clinic to understand its full potential.” Chunbo Li, Chairman of Zhejiang Medicine, commented, “We are honored to partner with Ambrx, a leading biotech company, in ADC drugs. We will work with WuXi PharmaTech to accelerate the development and commercialization of ARX788...

Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates

SAN DIEGO May 3, 2013 Ambrx today entered into a collaboration agreement with Bristol-Myers Squibb (NYSE: BMY) for the discovery and development of novel antibody drug conjugates using Ambrx’s protein medicinal chemistry technology. Under terms of the agreement, Ambrx will receive an upfront payment of $15 million, funding for discovery and research activities, and potential development, regulatory and sales based milestone payments of up to $97 million per product resulting from the collaboration. Bristol-Myers Squibb will receive worldwide rights to develop and commercialize products resulting from the collaboration, and Ambrx is eligible to receive royalties on net sales. Additional terms were not disclosed. “Bristol-Myers Squibb is a global biopharmaceutical leader with expertise developing and commercializing novel medicines for the treatment of cancer and other diseases, and we are pleased to enter into a third collaboration with the company to include another aspect of our technology platform,” said Lawson Macartney, Ph.D., chief executive officer of Ambrx. “We look forward to working together to further utilize Ambrx’s technology to discover and advance these antibody drug conjugates for oncology indications.” Ambrx and Bristol-Myers Squibb entered into two separate agreements in September 2011 to research, develop and commercialize biologics created with Ambrx’s protein medicinal chemistry technology. These therapeutic candidates, which target the Fibroblast Growth Factor 21 (FGF-21) protein for the potential treatment of type 2 diabetes, and the Relaxin hormone for the potential treatment of heart failure, are being developed by Bristol-Myers Squibb. About Ambrx Ambrx Inc. is a clinical stage biopharmaceutical company using an expanded genetic code to create best-in-class biotherapeutics, including antibody drug conjugates, bispecific antibodies and proteins with improved pharmacologic...

Astellas and Ambrx Initiate Collaboration for Discovery and Development of Next-Generation Antibody Drug Conjugates for Oncology

TOKYO and SAN DIEGO April 4, 2013 Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) today entered into a collaboration with Ambrx Inc. (“Ambrx”) for the discovery and development of novel antibody drug conjugates (“ADCs”). ADCs allow for the targeted delivery of drugs to the target tissue. Ambrx creates optimized ADCs using its site-specific conjugation technology along with proprietary linkers and payloads. In the preclinical setting, Ambrx ADCs have demonstrated high potency and a wider therapeutic index than ADCs created using conventional non-specific conjugation. Ambrx will receive an upfront payment of $15 million from Astellas, as well as up to $285 million in potential near and long-term research, development, regulatory and sales based milestones for an undisclosed number of targets for ADCs in oncology. A portion of these milestones, as well as royalties on any net sales, will be contingent on eventual successful commercialization of products developed as a result of this partnership. Astellas will receive worldwide rights to develop and commercialize ADCs for oncology. Additional terms of the collaboration are not disclosed at this time. “Agensys, Inc., an affiliate of Astellas which specializes in therapeutic antibody research and development in cancer, has significant experience with ADCs as oncology therapeutics and is looking to further expand its capabilities in this area. Ambrx offers a novel approach to allow creation of site-specific and highly stable conjugations that have the potential to further optimize drug delivery to tumor cells.” said David Stover, Ph.D., Senior Vice President and Agensys Site Head. Added Lawson Macartney, chief executive officer of Ambrx, “We recognize Astellas as a leader in the development of innovative therapeutics for oncology and...

Ambrx Collaborates with Merck to Design and Develop Biologic Drug Conjugates

San Diego, CA June 18, 2012 Ambrx today announced that the company has entered into a collaboration with Merck to design and develop rationally optimized biologic drug conjugates based on Ambrx’s site-specific protein medicinal chemistry technology. “Ambrx’s technology has the potential to provide the foundation for a new family of biologic drug conjugates that selectively deliver small molecules to their site of action,” said Peter G. Schultz, Ph.D., a scientific founder and board member. “Merck’s deep disease area expertise made it the partner of choice in expanding the application of this technology beyond oncology to other important disease areas.” Under the terms of the agreement, Merck gains worldwide rights to develop and commercialize biotherapeutic drug conjugates directed towards a number of pre-specified targets. Ambrx will receive an upfront payment of $15 million and is eligible to receive milestone payments totaling up to $288 million for successful discovery, development and commercialization of candidates to all pre-specified targets. In addition, Ambrx will receive royalties on any net sales of products resulting from the collaboration. “Collaborations are an important part of our strategy to develop a portfolio of next generation protein therapeutics that may offer significant benefits to patients,” said Richard Murray, Ph.D., senior vice president and head of biologics and vaccines research at Merck. “This agreement will allow us to combine Ambrx’s expertise in site-specific protein conjugation chemistry with Merck’s expanding antibody capabilities and extensive small molecule resources.” By combining the targeting properties of biologics with the potent therapeutic properties of small molecules, Merck and Ambrx plan to design and optimize new ways to specifically deliver pharmacologically active compounds to their...